47
Participants
Start Date
September 15, 2005
Primary Completion Date
April 14, 2014
Study Completion Date
October 15, 2018
Alemtuzumab (Campath )
Campath administered at a dose of 10/mg/day for 10 days
Cyclosporine
Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit. Dosing will be based on ideal body weight and will be adjusted to maintain a target level of 200 - 400 ng /ml.
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Heart, Lung, and Blood Institute (NHLBI)
NIH